Results 1 to 10 of about 54,594 (319)

The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade [PDF]

Frontiers in Immunology
BackgroundThe introduction of checkpoint immunotherapeutic agents in the last decade has revolutionized cancer treatment. Although anti-PD-1, anti-PD-L1 and anti-CTLA4 are promising therapies, many patients fail to respond or relapse due to drug ...
Przemysław Bielski, Przemysław Bielski, Przemysław Bielski, Jan Barczyński, Jan Barczyński, Michał Mikitiuk, Michał Mikitiuk, Maja Myrcha, Kamil Rykała, Louis Boon, Wiktoria Gąsior, Aleksandra Hec-Gałązka, Tad A. Holak, Tomasz Sitar, Tomasz Sitar   +14 more
doaj   +2 more sources

Modular generation of multispecific antibodies using protein trans-splicing [PDF]

mAbs
Multispecific antibodies are exhibiting rapid growth in drug development due to their ability to engage multiple therapeutic targets and deliver unique functional properties inaccessible to conventional monoclonal antibodies.
Jared A. Shadish, John D. Bagert, Amber N. Lee, Kenneth K. Sharp, Chunning Yang, Yijia Li, Rui Wang, Seungwook Shin, Alina A. Malik, Jia Lin, Fengying Huang, Wenhai Liu, Yariv Mazor   +12 more
doaj   +2 more sources

A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration

Cell Reports, 2021
Summary: The dramatically expanding coronavirus disease 2019 (COVID-19) needs multiple effective countermeasures. Neutralizing nanobodies (Nbs) are a potential therapeutic strategy for treating COVID-19.
Xilin Wu, Lin Cheng, Ming Fu, Bilian Huang, Linjing Zhu, Shijie Xu, Haixia Shi, Doudou Zhang, Huanyun Yuan, Waqas Nawaz, Ping Yang, Qinxue Hu, Yalan Liu, Zhiwei Wu   +13 more
doaj   +1 more source

Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy. [PDF]

Antib Ther
Kang X, Zhao Y, Ling H, Huang X.
europepmc   +3 more sources

Bispecific antibody therapies

Hematology, 2023
Abstract Management of hematological malignancies is rapidly evolving from chemotherapy-based regimens toward targeted agents and immunotherapies, including bispecific antibodies (BsAbs). These novel and highly active treatments come with new side effect profiles.
de Assis, Luiz Henrique, Fassi, Daniel El, Hutchings, Martin   +2 more
openaire   +3 more sources

Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies

Pharmaceuticals, 2021
Solid tumors adopt multiple mechanisms to grow, evade immune responses, and to withstand therapeutic approaches. A major breakthrough in the armamentarium of anti-cancer agents has been the introduction of monoclonal antibodies (mAbs), able to inhibit ...
Gabriele Antonarelli, Federica Giugliano, Chiara Corti, Matteo Repetto, Paolo Tarantino, Giuseppe Curigliano   +5 more
doaj   +1 more source

T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions

Frontiers in Oncology, 2023
Several key advances in the treatment of B-cell non-Hodgkin lymphoma (B-NHL) over the past two decades have strategically exploited B-cell lineage markers suitable for targeting by immunotherapies. First, the addition of the anti-CD20 monoclonal antibody
David A. Russler-Germain, David A. Russler-Germain, Armin Ghobadi, Armin Ghobadi   +3 more
doaj   +1 more source

Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer

Frontiers in Immunology, 2023
The ErbB family of receptor tyrosine kinases is a primary target for small molecules and antibodies for pancreatic cancer treatment. Nonetheless, the current treatments for this tumor are not optimal due to lack of efficacy, resistance, or toxicity. Here,
Emilia Rabia, Véronique Garambois, Christine Dhommée, Christel Larbouret, Laurie Lajoie, Yoan Buscail, Yoan Buscail, Gabriel Jimenez-Dominguez, Sylvie Choblet-Thery, Emmanuelle Liaudet-Coopman, Martine Cerutti, Marta Jarlier, Patrice Ravel, Laurent Gros, Laurent Gros, Nelly Pirot, Nelly Pirot, Gilles Thibault, Eugene A. Zhukovsky, Pierre-Emmanuel Gérard, André Pèlegrin, Jacques Colinge, Thierry Chardès, Thierry Chardès, Thierry Chardès   +24 more
doaj   +1 more source

Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method

mAbs, 2023
A challenge when developing therapeutic antibodies is the identification of candidates with favorable pharmacokinetics (PK) early in development. A key determinant of immunoglobulin (IgG) serum half‑life in vivo is the efficiency of pH-dependent binding ...
Thomas Müller, Carolin Tasser, Michael Tesar, Ivica Fucek, Ute Schniegler-Mattox, Joachim Koch, Kristina Ellwanger   +6 more
doaj   +1 more source

Novel mesothelin antibodies enable crystallography of the intact mesothelin ectodomain and engineering of potent, T cell-engaging bispecific therapeutics

Frontiers in Drug Discovery, 2023
Mesothelin is a glypiated, cell-surface glycoprotein expressed at low levels on normal mesothelium but overexpressed by many cancers. Implicated in cell adhesion and multiple signaling pathways, mesothelin’s precise biological function and overall ...
Ida Lin, Peter B. Rupert, Kristina Pilat, Raymond O. Ruff, Della J. Friend, Man Kid Chan, Midori Clarke, Benjamin G. Hoffstrom, Jane Carter, Soheil Meshinchi, Ashok D. Bandaranayake, Christopher Mehlin, James M. Olson, Roland K. Strong, Colin E. Correnti   +14 more
doaj   +1 more source